Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep 1;192(5):544-50.
doi: 10.1164/rccm.201504-0829up.

Update in Pulmonary Vascular Diseases 2014

Elena A Goncharova, Mark T Gladwin, Steven M Kawut
Review

Update in Pulmonary Vascular Diseases 2014

Elena A Goncharova et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Novel genetic risk factors, gene modifiers, and new mechanisms underlying the pathogenesis of pulmonary hypertension. Up arrow indicates up-regulation; down arrow indicates down-regulation. A number in parentheses corresponds to a source article in the References. BMPR = bone morphogenic protein receptor; CMC = cardiomyocytes; COPD = chronic obstructive pulmonary disease; EC = endothelial cells; FOXO1 = forkhead box O transcription factor 1; GM-CSF = granulocyte macrophage colony-stimulating factor; HIF = hypoxia-inducible factor; IPF = idiopathic pulmonary fibrosis; miR = microRNA; mTORC2 = mammalian target of rapamycin complex 2; PAEC = pulmonary artery endothelial cells; PAH = pulmonary arterial hypertension; PAVSMC = pulmonary artery vascular smooth muscle cells; PH = pulmonary hypertension; PVOD = pulmonary venoocclusive disease; RV = right ventricular; SCD = sickle cell disease; SphK = sphingosine kinase; TopBP = topoisomerase DNA II–binding protein.
See this image and copyright information in PMC

References

    1. Pullamsetti SS, Schermuly R, Ghofrani A, Weissmann N, Grimminger F, Seeger W. Novel and emerging therapies for pulmonary hypertension. Am J Respir Crit Care Med. 2014;189:394–400. - PubMed
    1. Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, Hassoun PM, Hill NS, Humbert M, Kawut SM, Krowka M, et al. ATS Committee on Pulmonary Hypertension Phenotypes. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med. 2014;189:345–355. - PMC - PubMed
    1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41. - PubMed
    1. Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, et al. American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189:727–740. - PMC - PubMed
    1. Jiménez D, Kopecna D, Tapson V, Briese B, Schreiber D, Lobo JL, Monreal M, Aujesky D, Sanchez O, Meyer G, et al. On Behalf Of The Protect Investigators. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2014;189:718–726. - PubMed